Latest Regulatory Approvals News

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Bass Oil reported steady January production with a notable regulatory green light for its Vanessa gas field acquisition and a $3.5 million grant to accelerate the Kiwi gas field development.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

FIN Resources has completed the acquisition of the Cabin Lake Gold Project in Canada’s Northwest Territories, securing key permits and preparing for a fully funded drilling campaign starting in March 2026.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Basin Energy has executed a definitive agreement to sell its Marshall Uranium Project to Green Canada Corporation, securing upfront payments and retaining significant future upside through equity and buyback options.

Lunnon Metals reports a significant 49% increase in gold ounces at its Lady Herial deposit, now hosting 54,200 ounces, with mining operations underway and strong economic prospects supported by a binding Ore Purchase Agreement.

MinRex Resources Limited (ASX: MRR) has announced a definitive agreement to acquire 100% of Electrum Discovery Corp. (TSX-V: ELY) via a statutory Plan of Arrangement, creating a combined ASX-listed gold-copper exploration company with significant assets in Serbia and Australia.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.